Investment
Features
FeesSafety
Academy
More
Pluang+

Compare AMC ENTERTAINMENT HOLDINGS, INC. (AMC) vs Regeneron Pharmaceuticals Inc (REGN) Price & Performance

AMC ENTERTAINMENT HOLDINGS, INC.Trade
Regeneron Pharmaceuticals IncTrade

Price performance (Past 24H)

Key statistics

AMC ENTERTAINMENT HOLDINGS, INC. vs Regeneron Pharmaceuticals Inc — how do they compare? AMC ENTERTAINMENT HOLDINGS, INC. trades at $2.41 (market cap $2.16B), while Regeneron Pharmaceuticals Inc trades at $796.38 (market cap $83.19B). The key difference: Regeneron Pharmaceuticals Inc is far larger — about 38.5× AMC ENTERTAINMENT HOLDINGS, INC.'s market cap, and Regeneron Pharmaceuticals Inc pays the higher dividend (0.47%). Which is the better fit depends on your goals.

AMCREGN
Market Cap
$2.16B$83.19B
Sector
MediaHealth
52-Week High
$3.15$812.27
52-Week Low
$0.95$555.51
Enterprise Value
$9.10B$77.90B
Dividend Yield
0.11%0.47%

Aura AI Summary

Signals from Pluang's Aura AI — not financial advice

AMC ENTERTAINMENT HOLDINGS, INC.

AMC trades at $2.59, up 0.78% today, with a bullish technical signal and recent earnings beats. The stock is testing the $3.00 resistance level, supported by record box office performance and improved cash flow trends. However, the company remains unprofitable with a net income margin of -10.59% and high debt levels, though valuation ratios like P/S of 0.28 and P/B of 0.64 suggest potential undervaluation.

Outlook is cautiously optimistic due to strong revenue growth and cost discipline, but risks include persistent losses and heavy debt burden. Analyst consensus price target is $3.00, with 32% buy ratings, indicating moderate upside potential if operational improvements continue.

Regeneron Pharmaceuticals Inc

Regeneron Pharmaceuticals (REGN) trades at $784.36, up 1.59% today, with a bullish technical signal from moving averages but overbought RSI readings. The company shows strong profitability with a net income margin of 27.86% and has beaten EPS estimates in recent quarters. However, multiple class-action lawsuits filed in August 2026 allege inadequate clinical-trial risk disclosures, creating investor uncertainty amid solid financial performance.

Outlook remains supported by earnings momentum and analyst buy ratings, but legal risks and high valuation multiples pose near-term headwinds. Investment opportunity hinges on legal resolution and sustained drug pipeline success, while risks include trial setbacks and regulatory scrutiny.

Returns comparison

Trailing returns across standard periods

Top news

Latest headlines on both assets

About AMC ENTERTAINMENT HOLDINGS, INC.

AMC Entertainment Holdings, Inc. operates as a holding company. The Company, through its subsidiaries, provides theatrical exhibition, movie screening, food distribution, online ticket booking, and other related services. AMC Entertainment offers movie theaters worldwide.

Read more on AMC

About Regeneron Pharmaceuticals Inc

Regeneron Pharmaceuticals discovers, develops, and commercializes products that fight eye disease, cardiovascular disease, cancer, and inflammation. The company has several marketed products, including Eylea, approved for wet age-related macular degeneration and other eye diseases

Read more on REGN